Impact of the Orphan Drug Tax Credit for Rare Diseases
June 17, 2015
Today, the National Organization for Rare Disorders (NORD), Biotechnology Industry Organization (BIO), and Ernst & Young released “Impact of the Orphan Drug Tax Credit on Treatments for Rare Diseases,” a […]
NORD Issues Statement on Today’s Approval of the 21st Century Cures Initiative
May 21, 2015
NORD President and CEO Peter L. Saltonstall today issued the following statement on the approval by the House Energy and Commerce Committee of the 21st Century Cures legislative initiative and […]
NORD’s Paul Melmeyer Authors Piece in NCC Collaborator about State-Based Advocacy
March 16, 2015
NORD’s Assistant Director of Public Policy, Paul Melmeyer, authored this great piece (below) in the March 2015 issue of the NCC Collaborator, the monthly publication from the National Coordinating Center […]
